PROINTEX^® expands the range of products offered by Kolinpharma^®, introducing the company into a new therapeutic area: gastroenterology.

Thanks to active ingredients such as resveratrol, saffron extract, B vitamins, vitamin D, zinc, calcium and a unique blend of five probiotics, PROINTEX® aims to promote intestinal well-being and support digestive and psychological function.

Rita Paola Petrelli, President of KOLINPHARMA^®, commented: "To date, more than 3 million people in Italy suffer from Irritable Bowel Syndrome (IBS), a condition that affects young people, especially women, of working age and which, in its most severe form, can severely limit socialising and daily life, heavily impacting quality of life. IBS is a functional disorder which, due to the heterogeneity of its symptoms affecting both the intestine and the psychological sphere, is increasingly recognised today as a condition involving the gut-brain axis.

We have always looked to the future of nutraceuticals, and this new PROINTEX^® project is yet another confirmation of this. This initiative marks a milestone in Kolinpharma's expansion strategy, reaffirming our ambition for growth and the central role of our R&D department in innovation in the sector."